Hadassah

Hadassah Research Leads to Patent for Diabetes-Related Oral Delivery Technology

Thursday, Jan 22 2015

Oramed Pharmaceuticals Inc., focused on the development of oral drug delivery systems including an oral insulin pill based on Hadassah Medical Organization research, has received a patent from the Israel Patent Office for its invention, “Methods and Compositions for Oral Administrations of Exenatide.”

Eexenatide, a glucagon-like peptide-1 (GLP-1) analog, is a hormone which induces insulin release at increased glucose levels and causes a feeling of satiety, resulting in reduced food intake and weight loss. Currently, it is only marketed in injectable form. Oramed’s oral GLP-1 capsule, according to Oramed, could significantly increase compliance and become a valuable tool in the treatment of diabetes.

Oramed was founded in 2006 by Dr. Miriam Kidron, a senior researcher in the Diabetes Unit at Hadassah, who continues to serve as the company’s chief scientist. A pharmacologist and biochemist, Dr. Kidron earned her PhD in biochemistry from the Hadassah-Hebrew University and earned the Bern Schlanger Award for her work in diabetes research. Formerly a visiting professor at the Medical School at the University of Toronto, she is a member of the American, European, and Israeli diabetes associations.

Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Hadassah. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes, under an Investigational New Drug application with the United States Food and Drug Administration.

Read more

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Jan 11 2018

Hadassah’s Heart Institute: Innovation at the Forefront

Prof. Chaim Lotan, head of the Hadassah Medical Organization’s Heart Institute, has made it a personal objective to foster innovation in cardiovascular technology.

READ MORE ›
alt_text

Thursday, Jan 11 2018

Medical Clown Nehama’s Blog, Chapter Five: Out of Love

“I met Masha in the surgery waiting room at Hadassah Hospital Ein Kerem,” says Medical Clown Shira, as she proceeds to convey this story: Masha is a three-year-old girl who lives in Russia. Every three months, she comes to Hadassah for an oncological examination under full anesthesia.

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Drug Company Collaborates with Hadassah Liver Specialist in Fighting Liver Disease

Dr. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit, in its Institute of Gastroenterology and Liver Diseases, is collaborating with Can-Fite BioPharma Ltd. to explore further the healing effects of a new drug that has proven in preclinical studies to mitigate inflammatory diseases of the liver, such as NASH (non-alcoholic steatohepatitis).

READ MORE ›
alt_text

Wednesday, Jan 10 2018

Bedridden Teen Walks Again, Thanks to First-in-Israel Complex Spinal Surgery at Hadassah

Yusef Rabaya, age 19, spent most of his life in bed at home in Jenin. Born with cerebral palsy (CP), he could sit only if he was propped up. Standing was excruciating and dangerous--and could cause permanent paralysis.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More